To report the use and sequelae of intravitreal injection of bevacizumab (Avastin; Roche) in Eales disease with persistent active neovascularization and vitreomacular traction.Methods:
Intravitreal injection of bevacizumab was used to treat Eales disease with a persistent large neovascular frond, vitreous hemorrhage, and vitreomacular traction.Results:
After the injection, there was spontaneous relief of the vitreomacular traction and improvement in visual acuity. Rapid regression of the neovascular frond resulted in a traction retinal break, which was successfully managed with barrage laser photocoagulation.Conclusion:
Intravitreal injection of bevacizumab seems to be a good option in managing persistent neovascularization in Eales disease. These patients need regular follow-up to recognize the complications that may arise due to the rapid regression of neovascularization.